frequent cardiovascular adverse events. 5 Therefore, peripheral ED as measured by FMD could be one of therapeutic targets for CAD patients. Also, increased arterial stiffness is associated with major cardiovascular risk factors and a strong predictor of prognosis in hypertensive patients. 6, 7 It can be assessed by a simple, noninvasive method of measuring brachial-ankle pulse wave velocity (baPWV), and the decrease in PWV has been suggested improved arterial compliance. 8, 9 According to previous studies, both FMD and baPWV were significant predictors of coronary events in patients with chronic CAD, and the addition of these vascular parameters had an incremental effect on the ability of traditional risk factors to predict future adverse outcomes. 10 Angiotensin II receptor blocker (ARB) is reported to have a blood pressure (BP)-independent protective effect on the endothelial function and arterial compliance. [11] [12] [13] ARB stimulates production of bradykinin and promotes NO production, thus enhancing endothelial function. 14, 15 A recent meta-analysis revealed the effect of a variety of ARBs on improving ED using FMD, which was superior to calcium channel blockers (CCB), beta-blockers and diuretics. 16 Several trials that analyzed the effect of candesartan showed a consistent increase in FMD ranging from 1.32% to 1.88%. [11] [12] [13] Not as much as FMD, but several previous studies reported that reduction in PWV was observed after short-term ARB treatment.
17,18
This study was aimed to identify the effect of candesartan on vascular reactivity and evaluate the predictors to control the candesartan's effect on vascular reactivity in patients with stable CAD.
| METHODS

| Study design
The study population was the pooled cohort from "Comparing the ef- 
| Study participants
Individuals aged 20 years or older with CAD were eligible in the study.
CAD was defined as (1) the presence of luminal narrowing ≥50% of the vessel diameter in at least one major coronary artery on coronary computed tomography or angiography; (2) a history of coronary revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG).
Patients were excluded if they had any of the following: (1) 
| Study design and treatment
The detailed study protocol was presented in the supplementary materials and Figure S1A . 
| Evaluation of study endpoints
The primary endpoint was the change in FMD and PWV from baseline to week 24. The endothelial function was measured by flow-mediated, Change of DBP (mm Hg) −9 ± 10 −8 ± 8 .719
FMD and PWV
Baseline FMD (%) 11.5 ± 4.9 6.0 ± 3.9 <.001 artery to obtain baPWV. 18 
| Statistical analysis
The analysis was performed by the full analysis set principle, including all the patients who received ≥1 dose of study drug, had a valid FMD and PWV measurement at baseline and at week 24. All descriptive data are expressed as either the mean ± standard deviation or percentages. The analyses, and P < .05 was considered statistically significant.
| RESULTS
| Study population
A total of 160 patients consented to participate in this study and were screened ( Figure S1B ). Of these, 124 were included in the analysis, and the baseline characteristics of all 124 patients are shown in Table S1 . The results of comparison between generic and original formula of candesartan were comparable and were presented in Table S2 and Figure S2 . We analyzed the effect of candesartan in the pooled cohort. After 24 weeks of maintenance treatment, the systolic and diastolic BP decreased significantly (from 139 ± 16 to 128 ± 20 mm Hg, from 82 ± 8 to 73 ± 9 mm Hg, respectively, both P < .001) in the study patients. FMD showed T A B L E 2 Multivariable logistic regression for the better responder of ED improvement F I G U R E 2 ROC curve of the baseline FMD and PWV for predicting better responder. (A) ROC curve of the baseline FMD for predicting better responder of FMD. AUC was 0.815 (95% CI 0.740-0.891, P < .001), and baseline FMD 7.5% showed optimal predictive value (sensitivity 79%, specificity 79%). (B) ROC curve of the baseline PWV for predicting better responder of PWV. AUC was 0.645 (95% CI 0.548-0.742, P = .005), and baseline PWV 1553 cm/s was optimal predictive value (sensitivity 68%, specificity 58%). AUC, area under the curve; FMD, flowmediated dilation; PWV, pulse wave velocity; ROC, receiver operating characteristic to 1552 ± 297 cm/s, P < .001).
| Predictors for improvement of endothelial function by candesartan
A subgroup analysis for identifying better responder of candesartan on ED improvement was performed. The better responder was defined as the upper half of the change of FMD (FMD change ≥1.3%, Figure S3A ). The comparison of the baseline characteristics of better and poor responders (Table 1) revealed that only baseline FMD was significantly lower in better responder group, while other parameters did not show a difference. There was a significant positive inverse correlation between baseline FMD and change of FMD (P < .001) ( Figure 1A ). In multivariable logistic regression analysis for searching the predictive factors for better responders, baseline FMD was the only significant predictor (odd ratio (OR) to be better responders 1.31
for 1% decrease in baseline FMD, 95% confidence interval (CI) 1.180-1.444, P < .001) ( Table 2) .
Receiver operating characteristic analysis was performed, and we investigated the optimal threshold of baseline FMD for predicting the better responder. Area under the curve (AUC) was 0.815 (95% CI 0.740-0.891, P < .001), and baseline FMD 7.5% showed optimal predictive value (sensitivity 79%, specificity 79%) (Figure 2A ).
Patients with baseline FMD <7.5 (n = 64) showed statistically significant improvement in ED (baseline vs post-treatment, 4.6 ± 1.7 vs 8.7 ± 4.4%FMD, P < .001). In univariable analysis, patients with low baseline FMD (<7.5%) were 11.8 times more likely to be better re- baPWV, brachial-ankle pulse wave velocity; CABG, coronary artery bypass graft surgery; CRP, C-reactive protein; CVA, cerebrovascular accident; DBP, diastolic blood pressure; FMD, flow-mediated dilation; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.
Values are n (%) or mean ± SD.
T A B L E 3 (Continued)
F I G U R E 3 Scatterplot showing the correlation between change in FMD and PWV (P = .733). Poor responder to candesartan in both FMD and PWV defined as change in FMD less than 1.3% and change in PWV more than −100 cm/s. Poor responder (both FMD and PWV, n = 31) showed a higher prevalence of previous MI than other patients group (38.7% vs 17.2%, P = .013). FMD, flow-mediated dilation; MI, myocardial infarction; PWV, pulse wave velocity
| Predictor for improvement of arterial compliance by candesartan
The better responder of candesartan on arterial compliance was defined as the lower half of the change of PWV (PWV change ≤−100 cm/s, Figure S3B ). The comparison of the baseline characteristics of better and poor responders on PWV (Table 3) showed that the decreases in systolic and diastolic BP after treatment were significantly greater in better responder group (change in systolic BP, −7 ± 15 vs −13 ± 19 mm Hg, P = .027; diastolic BP, −7 ± 9 vs −10 ± 8 mm Hg, P = .024). Also, same as in FMD, baseline PWV was significantly higher in better responder group (1717 ± 322 vs 1563 ± 278 cm/s, P = .005).
There was a significant but modest inverse correlation between baseline PWV and change of PWV (r = −.373, P < .001) ( Figure 1B ). ROC analysis was performed to find the optimal threshold of baseline PWV for predicting the better responder. AUC was 0.645 (95% CI 0.548-0.742, P = .005), and baseline PWV 1553 cm/s was the optimal predictive value (sensitivity 68%, specificity 58%) ( Figure 2B ).
| Absence of association between FMD and PWV
There was no significant correlation between FMD and PWV before treatment (r = .073, P = .422), also after treatment (r = .09, P = .318) ( Figure 1C,D) .
| Combined analysis of FMD and PWV on candesartan's effect on vascular reactivity
We evaluated the characteristics of the patients whose FMD and PWV responses after treatment were both poor (change of FMD <1.3% and change of PWV >−100 cm/s, Figure 3 ). The poor responder group (n = 31) showed no significant difference in baseline characteristics than other patients (n = 93), but a higher prevalence of previous myocardial infarction (38.7% vs 17.2%, P = .013). In univariable analysis, patients with previous MI were 3.04 times more likely to be poor responders to candesartan treatment in terms of both ED and arterial stiffness improvement. In multivariate logistic regression, history of MI remained significantly associated with poor responses in FMD and PWV by candesartan (OR to be poor responders 3.3, 95% CI
1.310-8.277, P = .011) after adjustment for other clinical parameters such as the presence of DM, hypertension, and dyslipidemia.
| DISCUSSION
In the present study of CAD patients, the candesartan improved the endothelial dysfunction (ED) and arterial stiffness. Furthermore, baseline ED (FMD <7.5%) was an important predictor of better response to candesartan's effect on ED improvement. On the improvement of arterial stiffness, decreases BP after candesartan treatment and baseline arterial stiffness (PWV >1553 cm/s) were important factors for predicting better response. Combined analysis of FMD and PWV as parameters for assessing vascular reactivity showed that the poor responder group in both FMD and PWV had a higher prevalence of previous MI than other patients.
The effect of candesartan on endothelial function has been reported from several small-sized studies in patients with hypertension and/or CAD. In the previous studies, the study population had more clinical risk factors, a definite ED (baseline FMD <9%) or were prohibited from the use of other medications. 11, 13 The present study is the first large-scale study to identify efficacy of candesartan to improve ED and predictors on this effect. In addition, this study included normotensive as well as hypertensive patients with CAD and did not restrict the use of beta-blocker or statin. Therefore the results would be more easily applicable to the daily clinical practice. Several mechanisms of ARB in ED improvement have been suggested. ARB exerts an antioxidative action by inhibition of angiotensin II-stimulated NADPH activity, leading to reduction in superoxide production and nitric oxide degradation. 21 Furthermore, AT1 blocker reduces oxidative stress through induction of extracellular superoxide dismutase activity.
15
AT1 blocker also stimulates the AT2 receptor and then activates bradykinin/B2 receptor-mediated NO production. 9.6 ± 4.7%FMD, P = .134). The mean of FMD change in total study patients was 0.62 ± 5.94% for 6 months, and it was smaller than previous studies that restricted the study population to patients with moderate HTN or patients with impaired baseline FMD (less than 9%).
11-13
Therefore, we did a subgroup analysis to identify which patients could be a better responder to candesartan in terms of ED improvement.
Patients with poor baseline endothelial function could achieve more benefit on ED improvement by candesartan. These results suggest that the beneficial effect of ARB on endothelial function would be more apparent when the patients' profiles are worse in terms of ED or clinical risk factors. According to the comparison of baseline characteristics by change in FMD (Table 1) , baseline FMD was the only parameter that showed a statistically significant difference between better versus poor responders to candesartan. Also the baseline FMD showed significant correlation with the change of FMD ( Figure 1A ).
We divided study population by FMD changes using binary, tertile, and quartile values and thoroughly explored all variables that could predict the FMD changes. No matter how we divided the groups, baseline FMD was the only factor that showed a significant difference between better and poor responders to candesartan. The traditional clinical risk profiles were not significantly different between better versus poor responders to candesartan, such as the prevalence of diabetes, previous MI and multivessel disease, systolic BP, serum creatinine, and HDL-C levels. After adjusting these parameters in multivariable analysis, the baseline ED presented as low FMD was an independent and strong predictor of the better responder to candesartan in terms of ED improvement. In other words, the poorer the baseline endothelial function is the better effect of candesartan we could achieve.
Not only ED, but arterial stiffness has been regarded as an independent predictor for future cardiovascular events. 10, 22 The effect of ARB on arterial stiffness has been reported, and recently Peng et al.
23
suggested that ARB treatment significantly reduced carotid-femoral PWV (cfPWV) and baPWV in hypertensive patients by a meta-analysis.
However, they reported that particularly telmisartan and valsartan significantly reduced PWV. A few studies of candesartan treatment were included in the meta-analysis, and they were relatively smallsized studies. 24, 25 In the total population (n = 124), post-treatment PWV was significantly reduced compared to baseline PWV (baseline vs post-treatment PWV, 1640 ± 309 vs 1552 ± 297 cm/s, P < .001).
In our study, BP lowering after candesartan treatment was associated with improvement in arterial stiffness. The relation between effect of ARB on arterial stiffness and BP lowering was controversial.
Compared to diuretics, only ARB induced a significant decrease in PWV although both treatments showed similar decrease in BP. 26 AT1
blocker decreased mean BP and directly influenced on the arterial wall.
Also it reversed cardiac/vascular hypertrophy, improved NO release, and reduced vasoconstriction independent of BP. 14, 21, 27 According to the comparison of baseline characteristics by change in PWV (Table 3) , baseline PWV showed a significant difference between better and poor responders to candesartan. Both in FMD and PWV, patients with worse endothelial function and arterial compliance could get more benefit from candesartan treatment.
In this study, there was no correlation between FMD and PWV. This is similar to the previous study which reported only relatively weak correlations between FMD and PWV in healthy population. In this study, study patients administered two types of candesartan either generic or branded candesartan. Between two groups, there was no significant difference in the baseline characteristics, primary, and secondary endpoints. We concluded that the effects of generic and branded candesartan were comparable. The detailed results of the comparisons between two types of candesartan were presented in the supplementary materials.
| Study limitations
This study had several limitations. We analyzed the effect of candesartan on ED improvement using FMD measurement. However, it still remained uncertain whether the FMD improvement in serial follow-up could be a therapeutic target. One retrospective study suggested that improved FMD was related to a lower risk of future cardiovascular events. 5 Although the measurement of FMD is inevitably associated with several limitations such as the lack of normal cutoff values and interobserver variability, it may be used as a surrogate marker for cardiovascular outcomes.
We analyzed the factors that were associated with better response on vascular reactivity after candesartan treatment, and the poor baseline endothelial function was associated with good response on ED improvement. The regression to the mean should be considered when interpret this data. Although we considered this point, mean FMD value at week 24 of better responders was still significantly higher than poor responders (Table 1) .
According to a meta-analysis of the ARB effect on ED improvement, the effect of ARB would not be well maintained more than 6 months. 12 There were few studies that had follow-up data after 6 months, and further investigation is needed to evaluate the longterm effect on ED.
| CONCLUSIONS
Our study demonstrated that the candesartan treatment was more beneficial in patients with more severe baseline endothelial dysfunction and arterial stiffness. Furthermore, poor responder group on both FMD and PWV as a surrogate marker for vascular reactivity showed higher prevalence of previous MI.
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